News · 26 weeks34+1000%
2026-03-012026-08-23
Mix1790d
- SEC Filings7(41%)
- Insider5(29%)
- Other3(18%)
- Leadership2(12%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Brosgart Carol L3 - Cocrystal Pharma, Inc. (0001412486) (Issuer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRCocrystal Pharma Appoints Carol Brosgart, MD to its Board of DirectorsBOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory. "Dr. Brosgart holds a distinguished record in antiviral drug development, having contributed to the development and FDA approval of therapies that have benefited patients worldwide," said Roger Kornberg, Ph.D., Chairm
- SECSEC Form 10-Q filed by Cocrystal Pharma Inc.10-Q - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECSEC Form SCHEDULE 13D filed by Cocrystal Pharma Inc.SCHEDULE 13D - Cocrystal Pharma, Inc. (0001412486) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Cocrystal Pharma Inc.SCHEDULE 13D/A - Cocrystal Pharma, Inc. (0001412486) (Subject)
- INSIDERDirector Frost Phillip Md Et Al bought $9,816 worth of shares (10,000 units at $0.98) (SEC Form 4)4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)
- INSIDERDirector Frost Phillip Md Et Al bought $70,590 worth of shares (75,000 units at $0.94) (SEC Form 4)4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRCocrystal Pharma Announces $5 Million Private Placement with OPKO HealthLongtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (NASDAQ:OPK) ("OPKO"), a longtime investor in the Company, has increased its position through a $5 million investment as the Company advances its lead norovirus program toward Phase 1b topline data later this year. Under the terms of the agreement, Cocrystal sold 5,474,053 shares of its common stock to OPKO at a price per share
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Sapirstein James4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sapirstein James3 - Cocrystal Pharma, Inc. (0001412486) (Issuer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRCocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive OfficerBOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin will continu
- SECSEC Form DEFA14A filed by Cocrystal Pharma Inc.DEFA14A - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECSEC Form DEF 14A filed by Cocrystal Pharma Inc.DEF 14A - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRCocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and InfluenzaNovel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenzaHantavirus and bunyavirus infections represent significant unmet medical needs, contribute to ongoing global outbreaks and have no approved treatments or vaccines BOTHELL, Wash., May 26, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces that its novel direct-acting antivirals demonstrate pan-viral activity against multiple viruses, including hantavirus, bunyavirus and influenza. These antiviral molecules target a highly conserved region of the viral replication enzyme, specifically the
- SECSEC Form 10-Q filed by Cocrystal Pharma Inc.10-Q - Cocrystal Pharma, Inc. (0001412486) (Filer)
- PRCocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial ResultsCompleted enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for norovirus infection, began enrollment in prevention and treatment cohortsHighlighted CDI-988's mechanism of action and clinical advancement at ICAR 2026Granted FDA Fast Track designation for CDI-988, enabling the potential for an accelerated development pathwayReceived initial $225,000 of SBIR NIH grant for influenza A and B antiviral lead generation BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") provides updates on its antiviral product pipeline and business activities and reports financial results
- SECSEC Form EFFECT filed by Cocrystal Pharma Inc.EFFECT - Cocrystal Pharma, Inc. (0001412486) (Filer)
- SECCocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)
COCP FAQ
5 questionsWhat does Cocrystal Pharma Inc. do?
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also...Where does COCP stock trade?
Cocrystal Pharma Inc. (COCP) is listed on NASDAQ.What sector and industry is COCP in?
Cocrystal Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to COCP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare COCP side-by-side with any of them on Quantisnow.How can I track COCP on Quantisnow?
Quantisnow aggregates Cocrystal Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow COCP to receive live email and push alerts on every new disclosure.